Global Nanopharmaceutical Drugs Market is Expected to Reach $79.29 Billion by 2026

Global Nanopharmaceutical Drugs Market is Expected to Reach $79.29 Billion by 2026

PR Newswire

FREMONT, California, December 11, 2018

FREMONT, California, December 11, 2018 /PRNewswire/ --

According to a new market intelligence report by BIS Research, titled 'Global Nanopharmaceutical Drugs Market - Analysis and Forecast, 2018-2026', the global nanopharmaceutical drugs market is anticipated to grow over $79.29 billion by 2026, growing at a CAGR of 8.12%, during the forecast period from 2018 to 2026. The growth of the market is aided by the remarkable growth in the liposome and polymer drug delivery systems.

     (Logo: )

Browse 22 market Data Tables and 194 Figures spread through 267 Pages and in-depth TOC on 'Global Nanopharmaceutical Drugs Market'.

Technological advancements in the healthcare industry have always played a crucial role in its development. Among the innumerable advancements witnessed by the industry, nanopharmaceuticals can provide rapid and sensitive detection of cancer-related targets, enabling scientists to detect molecular changes even when they occur only in a small percentage of cells. Nanotechnology when clubbed with healthcare has the potential to generate unique and highly effective therapeutic products. The recent advancements in the pharmaceutical industry, such as drug delivery at nano and microscopic level, investment in precision medicine, advancement in regenerative medicine, and genomic technologies, have led to big breakthroughs in the field of pharmaceutical research. Nanopharmaceutical provides new and promising pathways to combat genetic diseases and reduce the overall global economic burden.

The major factors driving the growth of this market, are government and private funding to support the development of regenerative medicine, rising prevalence of chronic diseases and genetic disorders, increase in the global healthcare expenditure, and rapid growth in the aging population. The main strategy of the pharmaceutical and biotechnology companies is to characterize the nanomedicine through research and development.  The idea is to perform the entire process within the company, with the help of an experienced team of researchers.  Business models between companies and research partners such as universities, or academic laboratories for the characterization of nanomaterial, would help reduce the company's cost. as researchers can frequently cofound the companies based on the discoveries made with the help of nanotechnology. Other options include research institutes licensing out the manufacturing and commercialization of the nanomedicine-based product to larger companies.

BIS Research Report:

Nanobiotechnology is a biological system invented at the molecular level and has helped in the development of pharmaceutical delivery devices. The delivery of conventional pharmaceuticals or substances such as peptides, recombinant proteins, vaccines and nucleotides are combined to nanoparticles such as micelles, liposomes, solid lipid nanoparticles, polymeric nanoparticles, functionalized nanoparticles, nanocrystals, cyclodextrins, dendrimers, nanotubes and metallic nanoparticles for site specific drug delivery. Significant progress has been made in the field of nanobiotechnology, resulting in the emergence of a huge number of medical products. By the end of 2020, one-third of research patents and many start-up companies in the nanomedicine are expected to engage in the applications of nanotechnology.

According to Abdul Wahid Analyst at BIS Research, "In 2017, North America was the leading contributor to the market with 51.8% of the market share in terms of revenue. Polymer drug carrier systems and liposome drug carrier systems are the two sub-segments that are expected to progress at significant rates, during the forecast period. Further, the significant development in the reimbursement policies, government regulations in the region are also expected to fuel the growth of the North America nanopharmaceutical drugs market. However, the market of Europe and Asia-Pacific are expected to grow at an impressive CAGR in terms of revenue during the forecast period.

Research Highlights: 

Request for a sample:

This market intelligence report provides a multidimensional view of the global nanopharmaceutical drugs market in terms of the market size and growth potential. This research report aims at answering various aspects of the global nanopharmaceutical drugs market with the help of the key factors driving the market, threats that can inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion.

Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities, such as product launches, regulatory clearance, and certifications, partnerships, collaborations, business expansions as well as mergers and acquisitions, among others. The research report provides a comprehensive analysis of the product sales and manufacturers and trend analysis by segments and demand analysis by regions.

This report is a meticulous compilation of research from the big pharmaceutical players in the market ecosystem and draws insights from in-depth interviews with the key opinion leaders of more than 30 leading companies, market participants, and vendors. The report also profiles 15 companies including several key players, such as Pfizer, Inc., AstraZeneca, Gilead Sciences, and Astellas Pharma Inc., Abbvie Inc., Amgen, Merck & Co., Inc., Hoffmann-La Roche AG., Teva Pharmaceuticals Industries Limited, Novartis AG, CELGENE CORPORATION, Sanofi S.A., JOHNSON & JOHNSON, AMAG Pharmaceuticals and Shire plc., among others.

Key questions answered in the report: 

Related Reports: 

Global Injectable Drug Delivery Market - Analysis and Forecast (2018-2025)

Global Drug Infusion Systems Market - Analysis and Forecast (2017-2025)

About BIS Research:  

BIS Research is a global B2B market intelligence and advisory firm focusing on those emerging technological trends which are likely to disrupt the dynamics of the market.

With over 150 market research reports published annually, BIS Research focuses on high technology verticals such as 3D Printing, Advanced Materials and Chemicals, Aerospace and Defense, Automotive, Healthcare, Electronics and Semiconductors, Robotics and UAV, and other emerging technologies.

Our in-depth market intelligence reports focus on the market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

What distinguishes BIS Research from the rest of the players is that we don't simply provide data but also complement it with valuable insights and actionable inputs for the success of our clients.

Bhavya Banga
BIS Research Inc.
FREMONT CA 94538-1686

Visit our Blog @

Connect with us on LinkedIn @

Connect with us on Twitter@

Voltar noticias em Inglês